CHIMERIC ANTIGEN RECEPTORS TARGETING HER2

(19)

(11)

EP 3 371 227 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	06.04.2022 Bulletin 2022/14

(45)	Mention of the grant of the patent:
	23.02.2022 Bulletin 2022/08

(21)	Application number: 16863128.1

(22)	Date of filing: 04.11.2016

(51)

International Patent Classification (IPC):

C07K 16/28^(2006.01)
C07K 14/705^(2006.01)
C12N 15/79^(2006.01)
A61K 39/00^(2006.01)
A61K 35/17^(2015.01)
C07K 16/32^(2006.01)
C12N 15/86^(2006.01)

C07K 16/30^(2006.01)
C12N 5/10^(2006.01)
C07K 14/725^(2006.01)
A61P 35/00^(2006.01)
C07K 14/71^(2006.01)
C12N 5/0783^(2010.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 35/17; C12N 15/86; C12N 2740/16043; C12N 2830/15; C07K 14/7051; C07K 14/70521; C07K 14/71; C07K 16/32; C12N 5/0636; A61K 2039/505; C07K 2317/622; C07K 2319/03; C07K 2319/33; A61P 35/00

(86)	International application number:
	PCT/US2016/060724

(87)	International publication number:
	WO 2017/079694 (11.05.2017 Gazette 2017/19)

(54)	CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 CHIMÄRE ANTIGENREZEPTOREN ZUM TARGETING VON HER2 RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES CIBLANT HER2

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

04.11.2015 US 201562251052 P

(43)	Date of publication of application:
	12.09.2018 Bulletin 2018/37

(60)	Divisional application:
	22157943.6

(73)	Proprietor: City of Hope
	Duarte, CA 91010 (US)

(72)	Inventors:
	PRICEMAN, Saul J. Duarte, CA 91010 (US) FORMAN, Stephen J. Duarte, CA 91010 (US) BROWN, Christine E. Duarte, CA 91010 (US)

(74)	Representative: Fish & Richardson P.C.
	Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München 80807 München (DE)

(56)

References cited: :

WO-A1-2014/100385
WO-A1-2015/028444
US-A1- 2009 252 729
US-A1- 2011 294 987
US-A1- 2014 099 309
US-A1- 2014 140 976
US-A1- 2015 306 141

WO-A1-2014/100385
WO-A2-2011/137245
US-A1- 2011 136 173
US-A1- 2012 301 447
US-A1- 2014 099 309
US-A1- 2014 140 976

Tobias Riët: "Erhöhung der Antigen-Selektivität von T-Zellen durch Koexpression chimärer Antigen-Rezeptoren unterschiedlicher Spezifität- Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln", , 24 November 2010 (2010-11-24), XP055252275, Retrieved from the Internet: URL:https://kups.ub.uni-koeln.de/3261/1/Di ssertation-TobiasRiet.pdf [retrieved on 2016-02-22]
Y. ZHAO ET AL: "A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 9, 20 October 2009 (2009-10-20), pages 5563-5574, XP055081967, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0900447
N. AHMED ET AL: "HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors", CLINICAL CANCER RESEARCH, vol. 16, no. 2, 15 January 2010 (2010-01-15), pages 474-485, XP055127702, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1322 -& N. AHMED ET AL: "Supplementary Data: HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors", CLINICAL CANCER RESEARCH, vol. 16, no. 2, 12 January 2010 (2010-01-12), pages 474-485, XP055489972, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1322
N. AHMED ET AL: "Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells", CANCER RESEARCH, vol. 67, no. 12, 15 June 2007 (2007-06-15) , pages 5957-5964, XP055170679, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-4309
MAHESH JONNALAGADDA ET AL: "Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy", MOLECULAR THERAPY, vol. 23, no. 4, 17 February 2015 (2015-02-17), pages 757-768, XP055242983, ISSN: 1525-0016, DOI: 10.1038/mt.2014.208
SAUL J. PRICEMAN ET AL: "Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 + Breast Cancer Metastasis to the Brain", CLINICAL CANCER RESEARCH, vol. 24, no. 1, 1 January 2018 (2018-01-01), pages 95-105, XP055564978, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-2041

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).